These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 29543705

  • 1. Glycycoumarin Sensitizes Liver Cancer Cells to ABT-737 by Targeting De Novo Lipogenesis and TOPK-Survivin Axis.
    Zhang E, Yin S, Lu X, Ye L, Fan L, Hu H.
    Nutrients; 2018 Mar 15; 10(3):. PubMed ID: 29543705
    [Abstract] [Full Text] [Related]

  • 2. Glycycoumarin exerts anti-liver cancer activity by directly targeting T-LAK cell-originated protein kinase.
    Song X, Yin S, Zhang E, Fan L, Ye M, Zhang Y, Hu H.
    Oncotarget; 2016 Oct 04; 7(40):65732-65743. PubMed ID: 27582549
    [Abstract] [Full Text] [Related]

  • 3. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
    Hari Y, Harashima N, Tajima Y, Harada M.
    Oncotarget; 2015 Dec 08; 6(39):41902-15. PubMed ID: 26506422
    [Abstract] [Full Text] [Related]

  • 4. Norcantharidin combined with ABT-737 for hepatocellular carcinoma: Therapeutic effects and molecular mechanisms.
    Ren J, Li G, Zhao W, Lin L, Ye T.
    World J Gastroenterol; 2016 Apr 21; 22(15):3962-8. PubMed ID: 27099439
    [Abstract] [Full Text] [Related]

  • 5. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
    Simonin K, N'Diaye M, Lheureux S, Loussouarn C, Dutoit S, Briand M, Giffard F, Brotin E, Blanc-Fournier C, Poulain L.
    Apoptosis; 2013 Apr 21; 18(4):492-508. PubMed ID: 23344663
    [Abstract] [Full Text] [Related]

  • 6. Increased efficacy of CDDP in a xenograft model of hepatoblastoma using the apoptosis sensitizer ABT-737.
    Lieber J, Dewerth A, Wenz J, Kirchner B, Eicher C, Warmann SW, Fuchs J, Armeanu-Ebinger S.
    Oncol Rep; 2013 Feb 21; 29(2):646-52. PubMed ID: 23229825
    [Abstract] [Full Text] [Related]

  • 7. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
    Witham J, Valenti MR, De-Haven-Brandon AK, Vidot S, Eccles SA, Kaye SB, Richardson A.
    Clin Cancer Res; 2007 Dec 01; 13(23):7191-8. PubMed ID: 18056200
    [Abstract] [Full Text] [Related]

  • 8. HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2.
    Yang H, Lee MH, Park I, Jeon H, Choi J, Seo S, Kim SW, Koh GY, Park KS, Lee DH.
    Cancer Lett; 2017 Dec 28; 411():19-26. PubMed ID: 28987383
    [Abstract] [Full Text] [Related]

  • 9. ABT-737 Synergizes with Cisplatin Bypassing Aberration of Apoptotic Pathway in Non-small Cell Lung Cancer.
    Kim EY, Jung JY, Kim A, Chang YS, Kim SK.
    Neoplasia; 2017 Apr 28; 19(4):354-363. PubMed ID: 28319809
    [Abstract] [Full Text] [Related]

  • 10. The BH3 mimetic ABT-737 increases treatment efficiency of paclitaxel against hepatoblastoma.
    Lieber J, Eicher C, Wenz J, Kirchner B, Warmann SW, Fuchs J, Armeanu-Ebinger S.
    BMC Cancer; 2011 Aug 19; 11():362. PubMed ID: 21854558
    [Abstract] [Full Text] [Related]

  • 11. Combined antitumor effect of γ-secretase inhibitor and ABT-737 in Notch-expressing non-small cell lung cancer.
    Sakakibara-Konishi J, Ikezawa Y, Oizumi S, Kikuchi J, Kikuchi E, Mizugaki H, Kinoshita I, Dosaka-Akita H, Nishimura M.
    Int J Clin Oncol; 2017 Apr 19; 22(2):257-268. PubMed ID: 27816990
    [Abstract] [Full Text] [Related]

  • 12. ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation.
    Russo M, Spagnuolo C, Volpe S, Tedesco I, Bilotto S, Russo GL.
    Biochem Pharmacol; 2013 Apr 01; 85(7):927-36. PubMed ID: 23353698
    [Abstract] [Full Text] [Related]

  • 13. Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition.
    Tamaki H, Harashima N, Hiraki M, Arichi N, Nishimura N, Shiina H, Naora K, Harada M.
    Oncotarget; 2014 Nov 30; 5(22):11399-412. PubMed ID: 25333266
    [Abstract] [Full Text] [Related]

  • 14. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
    Iacovelli S, Ricciardi MR, Allegretti M, Mirabilii S, Licchetta R, Bergamo P, Rinaldo C, Zeuner A, Foà R, Milella M, McCubrey JA, Martelli AM, Tafuri A.
    Oncotarget; 2015 Oct 13; 6(31):32089-103. PubMed ID: 26392332
    [Abstract] [Full Text] [Related]

  • 15. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms.
    Kuroda J, Kimura S, Andreeff M, Ashihara E, Kamitsuji Y, Yokota A, Kawata E, Takeuchi M, Tanaka R, Murotani Y, Matsumoto Y, Tanaka H, Strasser A, Taniwaki M, Maekawa T.
    Br J Haematol; 2008 Jan 13; 140(2):181-90. PubMed ID: 18028486
    [Abstract] [Full Text] [Related]

  • 16. Clitocine induces apoptosis and enhances the lethality of ABT-737 in human colon cancer cells by disrupting the interaction of Mcl-1 and Bak.
    Sun JG, Xiang J, Zeng XL, Li X, Wu P, Fung KP, Liu FY.
    Cancer Lett; 2014 Dec 28; 355(2):253-63. PubMed ID: 25304383
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer.
    Hann CL, Daniel VC, Sugar EA, Dobromilskaya I, Murphy SC, Cope L, Lin X, Hierman JS, Wilburn DL, Watkins DN, Rudin CM.
    Cancer Res; 2008 Apr 01; 68(7):2321-8. PubMed ID: 18381439
    [Abstract] [Full Text] [Related]

  • 18. Low-dose 5-fluorouracil sensitizes HepG2 cells to TRAIL through TRAIL receptor DR5 and survivin-dependent mechanisms.
    Yang L, Wang Y, Zheng H, Zhang D, Wu X, Sun G, Yang T.
    J Chemother; 2017 Jun 01; 29(3):179-188. PubMed ID: 28067150
    [Abstract] [Full Text] [Related]

  • 19. GDC-0941 sensitizes breast cancer to ABT-737 in vitro and in vivo through promoting the degradation of Mcl-1.
    Zheng L, Yang W, Zhang C, Ding WJ, Zhu H, Lin NM, Wu HH, He QJ, Yang B.
    Cancer Lett; 2011 Oct 01; 309(1):27-36. PubMed ID: 21664043
    [Abstract] [Full Text] [Related]

  • 20. Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737.
    Lucas KM, Mohana-Kumaran N, Lau D, Zhang XD, Hersey P, Huang DC, Weninger W, Haass NK, Allen JD.
    Clin Cancer Res; 2012 Feb 01; 18(3):783-95. PubMed ID: 22173547
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.